{"filing":{"accession_number":"0001649094-26-000041","cik":"0001649094","ticker":"PCVX","company_name":"Vaxcyte, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"pcvx-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805.htm"},"events":[{"id":25193,"run_id":22859,"accession_number":"0001649094-26-000041","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Vaxcyte issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $284.3 million, R\u0026D expenses of $267.9 million, and cash position of $2.5 billion. The filing explicitly states the press release is furnished as Exhibit 99.1 and incorporates financial statements showing operating results, which is the hallmark of an earnings release under Item 2.02.","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25953,"accession_number":"0001649094-26-000041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Vaxcyte issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $284.3 million, R\u0026D expenses of $267.9 million, and cash position of $2.5 billion. The filing explicitly states the press release is furnished as Exhibit 99.1 and incorporates financial statements showing operating results, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:10.890746+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25953,"accession_number":"0001649094-26-000041","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Vaxcyte issued a press release on August 5, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing Q2 2026 net loss of $284.3 million, R\u0026D expenses of $267.9 million, and cash position of $2.5 billion. The filing explicitly states the press release is furnished as Exhibit 99.1 and incorporates financial statements showing operating results, which is the hallmark of an earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:18:10.890746+00:00","company_name":"Vaxcyte, Inc.","ticker":"PCVX","filing_date":"2026-08-05"}]}